Brainstorm Cell Therapeutics Inc. (BCLI) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
0250K500K750K1M1M2M2M2MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Margin (%)

Gross MarginOperating MarginNet Income Margin
01122344556687990Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Operating Expenses

Research And Development ExpensesGeneral And Administrative Expenses
0500K1M2M2M2M3M4M4MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

EBITDA

EBITDA
-4M-3M-3M-2M-2M-1M-1000K-500K1Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025

EPS

Revenue Variation (%)

Revenue Variation
-200-175-150-125-100-74-49-241Q1 2025

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
048111519222630Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Revenue YoY Variation (%)

Revenue YoY Variation
0255075100125150175200Q4 2024

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
0255075100125150175200Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Price-to-Earning Ratio

P/E Ratio
-3-2-2-2-1-0001Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Income Breakdown

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
075K150K225K300K375K450K525K600KQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000001111Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Expense Ratios

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
011223445Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025
💰 Cash Flow Statement

Operating Cash Flow

Free Cash Flow

Cash At End Of Period
0625K1M2M2M3M4M4M5MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
0750K2M2M3M4M4M5M6MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025
🏦 Balance Sheet
📈 Key Metrics